相似文献
1
Simplification of isoniazid phenotyping procedure to promote its application in the chemotherapy of tuberculosis.简化异烟肼表型检测程序以促进其在结核病化疗中的应用。
Bull World Health Organ. 1973;49(5):507-16.
2
Screening of isoniazid inactivators by dilution test.通过稀释试验筛选异烟肼灭活剂。
Bull World Health Organ. 1974;51(4):428-30.
3
[Determination of isoniazid and acetylisoniazid in the urine for phenotyping isoniazid inactivators].[尿液中异烟肼和乙酰异烟肼的测定用于异烟肼灭活剂的表型分析]
Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi. 1983 Apr;6(2):71-3.
4
Isoniazid acetylation rates (phenotypes) of patients being treated for tuberculosis.正在接受结核病治疗患者的异烟肼乙酰化率（表型）。
Bull World Health Organ. 1971;45(5):617-24.
5
The value of urine testing for verifying adherence to anti-tuberculosis chemotherapy in children and adults in Uganda.乌干达儿童和成人尿液检测对验证抗结核化疗依从性的价值。
Int J Tuberc Lung Dis. 2002 Oct;6(10):903-8.
6
[The importance of estimating the individual acetylation rate in modern tuberculosis treatment].
Mikrobiyol Bul. 1979 Jan;13(1):53-61.
7
8
9
Simplified screening test for phenotyping of isoniazid inactivators.异烟肼灭活剂表型的简化筛查试验。
Int J Clin Pharmacol. 1973 Feb;7(1):82-6.
引用本文的文献
1
Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients.南非结核患者异烟肼群体药代动力学的变异性。
Br J Clin Pharmacol. 2011 Jul;72(1):51-62. doi: 10.1111/j.1365-2125.2011.03940.x.
2
Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic sclerosis.芳胺N-乙酰基转移酶2（NAT2）基因多态性与系统性硬化症之间无关联。
Eur J Clin Pharmacol. 2005 Jan;60(11):773-8. doi: 10.1007/s00228-004-0837-x. Epub 2004 Nov 24.
3
Evaluation of acetylator phenotype, renal function and serum sulfadiazine levels in patients with paracoccidioidomycosis treated with cotrimazine (a combination of sulfadiazine and trimethoprim).对接受复方磺胺甲恶唑（磺胺嘧啶和甲氧苄啶的组合）治疗的副球孢子菌病患者的乙酰化表型、肾功能和血清磺胺嘧啶水平进行评估。
Mycopathologia. 1989 Nov;108(2):107-12. doi: 10.1007/BF00436060.
4
Clinical pharmacokinetics of isoniazid.异烟肼的临床药代动力学
Clin Pharmacokinet. 1979 Nov-Dec;4(6):401-22. doi: 10.2165/00003088-197904060-00001.
本文引用的文献
1
[CONTRIBUTION TO A QUICK DIFFERENTIATION OF THE INDIVIDUAL ISONIAZID METABOLISM].
Prax Pneumol. 1964 Aug;18:535-41.
2
[A RAPID METHOD FOR DETERMINING THE CONCENTRATION OF INH EXCRETED THROUGH THE KIDNEYS].
Beitr Klin Tuberk Spezif Tuberkuloseforsch. 1964 May 27;128:213-7.
3
A NEW METHOD FOR THE DETERMINATION OF N-ACETYL ISONIAZID IN URINE OF AMBULATORY PATIENTS.一种测定门诊患者尿液中N-乙酰异烟肼的新方法。
Am Rev Respir Dis. 1964 Apr;89:587-8. doi: 10.1164/arrd.1964.89.4.587.
4
5
Peripheral neuritis due to isoniazid.异烟肼所致周围神经炎
Bull World Health Organ. 1960;23(4-5):587-98.
6
[The differentiation between isoniazid-inactivating and normally catabolizing patients by means of a simple test].
Beitr Klin Tuberk Spezif Tuberkuloseforsch. 1961;124:384-9.
7
[Experimental studies on dosage of isoniazid].[异烟肼剂量的实验研究]
Beitr Klin Tuberk Spezif Tuberkuloseforsch. 1961;124:310-9.
8
The quantitative determination of isoniazid and para-aminosalicylic acid in body fluids.体液中异烟肼和对氨基水杨酸的定量测定。
Am Rev Tuberc. 1957 Nov;76(5):852-61. doi: 10.1164/artpd.1957.76.5.852.
9
Studies on the metabolic basis for the genetically determined capacities for isoniazid inactivation in man.
J Pharmacol Exp Ther. 1965 Nov;150(2):298-304.
10
Method for the estimation of acetylisoniazid in urine.
Tubercle. 1968 Jun;49(2):210-6. doi: 10.1016/0041-3879(68)90023-8.
Zotero 插件